Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.177 (
BIS
)
957
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Three open-label extension trials evaluated the safety of budesonide inhalation suspension (
BIS
;
Pulmicort Respules
) in 670 children (8 months-9 years of age) with mild-to-severe persistent asthma. Patients were randomized to receive either
BIS
or conventional asthma therapy (CAT) for 52 weeks. The percentage of patients who discontinued because of clinical adverse events was low and similar among the CAT (0.4%) and
BIS
(0.7%) groups. After adjusting for length of time in the studies, there were no clinically relevant differences between the
BIS
and CAT groups in the type, incidence, or intensity of adverse events; vital signs or physical examination outcomes; or changes in clinical laboratory evaluations or oral fungal cultures.
...
PMID:Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. 1177 93
